{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938036",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938036_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"alendronate\" outputclass=\"int-drug\">alendronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"alendronate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/alendronic-acid.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4656\">alendronate</xref></ph> should be taken at least 30 minutes before <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   alendronate .  Manufacturer advises  alendronate  should be taken at least 30 minutes before  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alendronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938037",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938037_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of the active metabolite of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"baloxavir marboxil\" outputclass=\"int-drug\">baloxavir marboxil</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   might   decrease   the concentration of the active metabolite of   oral   baloxavir marboxil .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baloxavir marboxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938038",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938038_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bendroflumethiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938039",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938039_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlorothiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938040",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938040_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlortalidone   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938041",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938041_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"clodronate\" outputclass=\"int-drug\">clodronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph> for 2 hours before or 1 hour after <ph otherprops=\"clodronate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/sodium-clodronate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4681\">clodronate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   clodronate .  Manufacturer advises avoid  calcium phosphate  for 2 hours before or 1 hour after  clodronate .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clodronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938042",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938042_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   calcium phosphate   increases   the effects of   digoxin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938043",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938043_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dolutegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938044",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938044_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eltrombopag</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938045",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938045_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separating administration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   estramustine .  Manufacturer advises separating administration .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938046",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938046_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrochlorothiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938047",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938047_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydroflumethiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938048",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938048_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"ibandronate\" outputclass=\"int-drug\">ibandronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph> for at least 6 hours before or 1 hour after <ph otherprops=\"ibandronate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ibandronic-acid.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4671\">ibandronate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   is predicted to   decrease   the absorption of   oral   ibandronate .  Manufacturer advises avoid  calcium phosphate  for at least 6 hours before or 1 hour after  ibandronate .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibandronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938049",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938049_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indapamide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938050",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938050_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"levothyroxine\" outputclass=\"int-drug\">levothyroxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 4 hours</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   is predicted to   decrease   the absorption of   levothyroxine .  Manufacturer advises separate administration by at least 4 hours .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levothyroxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938051",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938051_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metolazone   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938052",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938052_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"risedronate\" outputclass=\"int-drug\">risedronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   risedronate .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risedronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938053",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938053_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"strontium\" outputclass=\"int-drug\">strontium</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the exposure to   strontium .  Manufacturer advises separate administration by 2 hours .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Strontium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938054",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938054_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xipamide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938055",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1643857938055_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"zinc\" outputclass=\"int-drug\">zinc</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   zinc .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zinc</title>"
					}
				}
			],
			"hasSearchLabel": " Calcium phosphate  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Calcium phosphate </title>"
			},
			"rdfs:label": "calcium phosphate"
		}
	]
}